Ichor Biologics Profile
Key Indicators
- Authorised Capital ₹ 16.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 9.00 Cr
as on 23-10-2024
- Company Age 3 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 196.16 Cr
as on 23-10-2024
- Revenue 94.07%
(FY 2023)
- Profit 71.11%
(FY 2023)
- Ebitda 53.17%
(FY 2023)
- Net Worth 112.24%
(FY 2023)
- Total Assets 52.91%
(FY 2023)
About Ichor Biologics
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 16.00 Cr and a paid-up capital of Rs 9.00 Cr.
The company currently has active open charges totaling ₹196.16 Cr.
Sudini Reddy and Sujana Sudini serve as directors at the Company.
- CIN/LLPIN
U24239TG2021PTC149331
- Company No.
149331
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Mar 2021
- Date of AGM
25 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ichor Biologics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sudini Reddy  | Managing Director | 05-Mar-2021 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sujana Sudini | Director | 05-Mar-2021 | Current |
Financial Performance and Corporate Structure Insights of Ichor Biologics.
Ichor Biologics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 94.07% increase. The company also saw a substantial improvement in profitability, with a 71.11% increase in profit. The company's net worth Soared by an impressive increase of 112.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ichor Biologics?
In 2023, Ichor Biologics had a promoter holding of 95.01% and a public holding of 4.99%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 25 Jan 2024 | ₹44.75 Cr | Open |
Axis Bank Limited Creation Date: 09 Jan 2024 | ₹50.00 Cr | Open |
Yes Bank Limited Creation Date: 28 Dec 2023 | ₹50.00 Cr | Open |
How Many Employees Work at Ichor Biologics?
Ichor Biologics has a workforce of 213 employees as of Jul 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ichor Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ichor Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
